This poster was presented at the 29th Annual U.S. Psychiatric & Mental Health Congress, held October 21-24, 2016, in San Antonio, Texas.
Introduction: Tardive dyskinesia (TD) is an involuntary movement disorder that results from prolonged exposure to dopamine-receptor antagonists and is often irreversible, affecting any body region. The AIMS is a 7-component scale, used to assess the severity of abnormal movements in TD. In ARM-TD, a randomized, double-blind, placebo-controlled trial, deutetrabenazine significantly reduced overall AIMS score in patients with moderate/severe TD compared with placebo (-3.0 vs -1.6, P=0.0188).
Objective: To analyze the treatment effect of deutetrabenazine on individual AIMS score components.
Methods: The change in AIMS score from baseline to Week 12 was analyzed for each component using a mixed-model for repeated-measures for patients with baseline AIMS ≥6, the intended ARM-TD study population.
Results: Analysis of the individual item-wise components indicated that treatment with deutetrabenazine was associated with a reduction in 6 of 7 AIMS component scores. The areas most improved by treatment were the jaw (deutetrabenazine: -0.77, Placebo: -0.18; treatment difference [95% CI]: -0.59 [-0.89, -0.29]) and lips/perioral area (-0.58, -0.22; -0.36 [-0.70, -0.025]). Other improved areas included: the tongue (treatment difference [95% CI]: -0.23 [-0.57, 0.12]), upper extremities (-0.23 [-0.50, 0.03]), neck, shoulders, and hips (trunk) (-0.18 [-0.48, 0.13]), and lower extremities (-0.09 [-0.37, 0.19]). Improvement was not observed in muscles of facial expression (0.14 [-0.18, 0.46]).
Conclusion: In patients with moderate/severe TD, deutetrabenazine was associated with a reduction in abnormal, involuntary movements in 6 of the 7 areas evaluated, including the extremities, trunk, and most parts of the head, as reflected by improvements in most AIMS components.